Caspase activation is required for antiviral treatment response in chronic hepatitis C virus infection

Hepatology

Volumn 43, Issue 6, 2006, Pages 1311-1316

  Volkmann, Xandra ^a   Cornberg, Markus ^a   Wedemeyer, Heiner ^a   Lehner, Frank ^a   Manns, Michael P ^a   Schulze Osthoff, Klaus ^b   Bantel, Heike ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CASPASE; INTERFERON; RIBAVIRIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE;

ADULT; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CASPASES; ENZYME ACTIVATION; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PROBABILITY; REFERENCE VALUES; RISK ASSESSMENT; ROC CURVE; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 33745535991     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21186     Document Type: Article

References (38)

1. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alpha-2b plus ribavirin compared with Interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965.
2. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alta-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
3. Bantel H, Schulze-Osthoff K. Apoptosis in hepatitis C virus infection. Cell Death Differ 2003;10:48-58.
4. Galle PR, Krammer PH. CD95-induced apoptosis in human liver disease. Semin Liver Dis 1998;18:141-151.
5. Lau JYN, Xie X, Lai M, Wu PC. Apoptosis and viral hepatitis. Semin Liver Dis 1998;18:169-176.
6. Patel T, Roberts LR, Jones BA, Gores GJ. Dysregulation of apoptosis as a mechanism of liver disease: an overview. Semin Liver Dis 1998;18:105-114.
7. Fischer U, Janicke RU, Schulze-Osthoff K. Many cuts to ruin: a comprehensive update of caspase substrates. Cell Death Differ 2003;10:76-100.
8. Bantel H, Ruck P, Schulze-OsthofF K. In situ monitoring of caspase activation in hepatobiliary diseases. Cell Death Differ 2000;7:504-505.
9. Schwerk C, Schulze-Osthoff K. Non-apoptotic functions of caspases in cellular proliferation and differentiation. Biochem Pharmacol 2003;66:1453-1458.
10. Calabrese F, Pontisso P, Pettenazzo E, Benvegnu L, Vario A, Chemello L, et al. Liver cell apoptosis in chronic hepatitis C correlates with histological but not biochemical activity or serum HCV-RNA levels. HEPATOLOGY 2000;31:1153-1159.
11. Bantel H, Lügering A, Poremba C, Lügering N, Held J, Domschke W, et al. Caspase activation correlates with the degree of inflammatory liver injury in chronic hepatitis C virus infection. HEPATOLOGY 2001;34:758-767.
12. Bantel H, LügeringA, Heidemann J, Volkmann X, Poremba C, Strassburg CP, et al. Detection of caspase activation in the sera from patients with chronic HCV infection is associated with fibrotic liver injury. HEPATOLOGY 2004;40:1078-1087.
13. Los M, Wesselborg S, Schulze-Osthoff K. The role of caspases in development, immunity, and apoptotic signal transduction: lessons from knockout mice. Immunity 1999;10:629-639.
14. Yoon JH, Gores GJ. Death receptor-mediated apoptosis and the liver. J Hepatol 2002;37:400-410.
15. Hiramatsu N, Hayashi N, Katayama K, Mochizuki K, Kawanishi Y, Kasahara A, et al. Immunohistochemical detection of Fas antigen in liver tissue of patients with chronic hepatitis C. HEPATOLOGY 1994;19:1354-1359.
16. Mita E, Hayashi N, Iio S, Takehara T, Hijioka T, Kasahara A, et al. Role of Fas ligand in apoptosis induced by hepatitis C virus infection. Biochem Biophys Res Commun 1994;204:468-474.
17. Sedger LM, Shows DM, Blanton RA, Peschon JJ, Goodwin RG, Cosman D, et al. IFN-gamma mediates a novel antiviral activity through dynamic modulation of TRAIL and TRAIL receptor expression. J Immunol 1999;163:920-926.
18. Sato K, Hida S, Takayanagi H, Yokochi T, Kayagaki N, Takeda K, et al. Antiviral response by natural killer cells through TRAIL gene induction by IFN-alpha/beta. Eur J Immunol 2001;31:3138-3146.
19. Balachandran S, Kim CN, Yeh WC, Mak TW, Bhalla K, Barber GN. Activation of the dsRNA-dependent protein kinase, PKR, induces apoptosis through FADD-mediated death signaling. EMBO J 1998;17:6888-6902.
20. Cornberg M, Hadem J, Herrmann E, Schuppert F, Reiser M, Schmidt H, et al. Treatment with daily consensus interferon (CINF) plus ribavirin in non-responder patients with chronic hepatitis C: A randomized open-label pilot study. J Hepatol 2006;44:291-301
21. Ishak K, Baptists A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-699.
22. Seidel N, Volkmann X, Laenger F, Flemming P, Manns MP, Schulze-Osthoff K, et al. The extent of liver steatosis in chronic hepatitis C virus infection is mirrored by caspase activity in serum. HEPATOLOGY 2005;42:113-120.
23. Lechner F, Wong DKH, Dunbar PR, Chapman R, Chung RT, Dohrenwend P, et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000;191:1499-1512.
24. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005;5:215-229.
25. Thimme R, Bukh J, Spangenberg HC, Wieland S, Pemberton J, Steiger C, et al. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci U S A 2002;99:15661-15666.
26. Chisari FV. Cytotoxic T cells and viral hepatitis. J Clin Invest 1997;99:1472-1477.
27. Barber GN. Host defense, viruses and apoptosis. Cell Death Differ 2001;8:113-8126.
28. Balachandran S, Thomas E, Barber GN. A FADD-dependent innate immune mechanism in mammalian cells. Nature 2004;432:401-415.
29. Tan SL, Katze MG. How hepatitis C virus counteracts the Interferon response: the jury is still out on NS5A. Virology 2001;284:1-12.
30. Gao B, Hong F, Radaeva S. Host factors and failure of interferon-alpha treatment in hepatitis C virus. HEPATOLOGY 2004;39:880-890.
31. Pawlotsky JM. Hepatitis C virus resistance to antiviral therapy. HEPATOLOGY 2000;32:889-896.
32. Anatol P, Danuta P, Janusz D, Bozena P. Expression of Bcl-2 protein in chronic hepatitis C: Effect of interferon alpha 2b with ribavirin therapy. World J Gastroenterol 2005;11:2949-2952.
33. Scheller C, Sopper S, Chen P, Flory E, Koutsilieri E, Racek T, et al. Caspase inhibition activates HIV in latently infected cells. Role of tumor necrosis factor receptor 1 and CD95. J Biol Chem 2002;277:15459-15464.
34. Cuconati A, Degenhardt K, Sundararajan R, Anschel A, White E, Bak and Bax function to limit adenovirus replication through apoptosis induction. J Virol 2002;76:4547-4558.
35. Akira S. The role of IL-18 in innate immunity. Curr Opin Immunol 2000;12:59-63.
36. Murata K, Yamamoto N, Kawakita T, Saito Y, Yamanaka Y, Sugimoto K, et al. Up-regulation of IL-18 by interferon alpha-2b/ribavirin combination therapy induces an anti-viral effect in patients with chronic hepatitis C. Hepatogastroenterology 2005;52:547-551.
37. Sedger LM, Shows DM, Blanton RA, Peschon JJ, Goodwin RG, Cosman D, et al. IFN-gamma mediates a novel antiviral activity through dynamic modulation of TRAIL and TRAIL receptor expression. J. Immunol 1999;163:920-926.
38. Mundt B, Kuhnel F, Zender L, Paul Y, Tillmann H, Trautwein C, et al. Involvement of TRAIL and its receptors in viral hepatitis. FASEB J 2003;17:94-96.